p53 status research helps to define the role of genetic tests
This article was originally published in Clinica
Conclusive evidence that mutations in the p53 gene affect a patient's response to a certain cancer drug has opened the way for further work on identifying which patients respond best to certain treatments.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.